UK-PBC, which is funded by a grant from the Medical Research Council (MRC),has been acknowledged in their Annual Report and Accounts for the 2016/17 year. The MRC has recognised the coordinated work carried out by UK-PBC in collaboration with industry partners that has led to the United States Food and Drug Administration (FDA) to approve Ocaliva as a treatment for PBC. Ocaliva, a drug manufactured by Intercept Pharmaceuticals is the first new drug approved for use in PBC in 20 years.
FDA validation was followed quickly by EU Marketing Authorisation in January 2017. The National Institute for Health and Care Excellence (NICE) approved the treatment in March 2017 following UK-PBC evidence given at the review panel.
You can read the MRC Full Annual Report by following the links below.